ACON
What one share of Aclarion holds
Services – Medical Laboratories
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), and proprietary biomarkers to optimize clinical treatments. Aclarion’s technology addresses the $134.5B U.S. low back and neck pain market, which according to a 2020 JAMA (Journal of the American Medical Association) article is now the most costly healthcare condition in the United States.
Aclarion’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.06 |
|---|---|
| Profit | −$6.22 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$5.48 |
| Cash and investments | $6.61 |
| Debt | $0.00 |
| Book value | $6.91 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.07 | −$6.58 | — | −$2.65 | — | −$14.17 |
| 2022 | $0.16 | −$19.61 | — | −$12.97 | — | $4.53 |
| 2025 | $0.14 | −$13.61 | $0.04 | −$13.51 | — | $15.02 |